Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $10.12: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 6.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as... Read more
Sell if holding. Engine safety override at $10.12: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 6.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum. Chart setup: RSI 45 mid-range, Bollinger mid-band. Score 4.8/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 3d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $10.12: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 6.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum. Chart setup: RSI 45 mid-range, Bollinger mid-band. Prior stop was $9.35. Score 4.8/10, moderate confidence.
Take-profit target: $18.27 (+81.8% upside). Prior stop was $9.35. Stop-loss: $9.35.
Quality below floor (1.4 < 4.0).
Oric Pharmaceuticals, Inc. trades at a P/E of N/A (forward -6.4). TrendMatrix value score: 9.0/10. Verdict: Sell.
21 analysts cover ORIC with a consensus score of 4.3/5. Average price target: $21.
What does Oric Pharmaceuticals, Inc. do?ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of...
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.